68Ga-DOTATATE PET/CT与177Lu-DOTATATE SPECT/CT对肝转移灶的差异检出
本文报道一名58岁男性转移性高分化胰腺神经内分泌肿瘤患者,MRI显示肝转移灶进展。为评估肽受体放射性核素治疗(PRRT)资格而行68Ga-DOTATATE PET/CT,肝内未见DOTATATE摄取病灶,18F-FDG PET/CT肝内亦阴性;患者接受177Lu-DOTATATE PRRT后,多时间点治疗后平面显像和SPECT/CT显示已知肝转移灶强烈摄取。
要点
- 68Ga-DOTATATE PET/CT肝内未见DOTATATE摄取病灶,而177Lu-DOTATATE治疗后SPECT/CT显示已知肝转移灶强烈摄取。
- 18F-FDG PET/CT肝内亦为阴性。
- 68Ga-DOTATATE PET/CT对肝内较小病灶的可检出性较低。
核心结论
- 68Ga-DOTATATE PET/CT虽高度敏感,但对较小病灶尤其肝内病灶的可检出性较低。
- 本例68Ga-DOTATATE PET/CT肝内未见DOTATATE摄取病灶,而177Lu-DOTATATE治疗后SPECT/CT显示已知肝转移灶强烈摄取。
研究设计与样本
- 本文为病例报告,患者为58岁男性转移性高分化胰腺神经内分泌肿瘤。
主要发现
- MRI显示肝转移灶进展。
- 为确定PRRT资格行68Ga-DOTATATE PET/CT,肝内未见DOTATATE摄取病灶。
- 18F-FDG PET/CT肝内亦为阴性。
- 患者接受177Lu-DOTATATE PRRT,多时间点治疗后平面显像和SPECT/CT显示已知肝转移灶强烈摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68 Ga-DOTATATE PET/CT is indicated for selecting patients for peptide receptor radionuclide therapy (PRRT). Although highly sensitive, the detectability of smaller lesions, particularly in the liver, is lower. We present the case of a 58-year-old man with metastatic well-differentiated pancreatic neuroendocrine tumor whose MRI revealed progression of hepatic metastases. 68 Ga-DOTATATE PET/CT performed to determine eligibility for PRRT did not demonstrate DOTATATE-avid disease within the liver. 18 F-FDG PET/CT was also negative at the liver and the patient proceeded to 177 Lu-DOTATATE PRRT, where multi-time point posttherapy planar imaging and SPECT/CT showed intense uptake in the known liver metastases.
引用
- Zahed H, Beauregard JM, Abikhzer G, et al. Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CT. Clin Nucl Med. 2022. PMID: 36240803. doi:10.1097/RLU.0000000000004434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。